2、百奥赛图(北京)医药科技股份有限公司于2025-12-10上市，公司主营业务为从事提供基因编辑服务、 临床前药理药效评估服务、模式动物销售、抗体开发及创新药开发。 3、百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司 通过五个分部开展业务。 来源：新浪证券-红岸工作室 2月26日，百奥赛图涨8.15%，成交额2.11亿元，换手率7.92%，总市值346.39亿元。 异动分析 AI智能体+科创次新股+CRO概念+人民币贬值受益+注册制次新股 1、2026年1月13日互动易：我们通过AI的本地化部署，正在建设抗体药物研发AI智能体。随着千鼠万 抗计划与AI系统深度整合的持续推进，我们将为全球药企提供更加高效的研发工具和更为丰富的抗体 分子库，帮助药企伙伴提高临床前PCC分子的研发效率，这也将推动抗体发现业务迈入全新发展阶段。 区间今日近3日近5日近10日近20日主力净流入218.42万-921.89万-975.39万2306.19万7132.04万 公司简介 4、根据2024年年报，公司海外营收占比为67.94%，受益于人民币贬值。 5、百奥赛图(北京)医药科技股份有限 ...

Market Performance - The Sci-Tech Innovation 50 Index opened lower on December 10, fluctuating throughout the day, ultimately closing at 1346.7 points with a slight decline of 0.03% and a total trading volume of approximately 55.36 billion yuan [1] - The overall Sci-Tech Innovation Index rose by 0.14% to close at 1604.56 points, with a total trading volume of 180.3 billion yuan [1] - Among the 595 stocks in the Sci-Tech board, there were more decliners than gainers, with semiconductor and communication equipment stocks performing strongly, while electrical equipment and software service stocks saw significant declines [1] Company Highlights - Bai'ao Saitou was listed on the Sci-Tech board on December 10, with a stock code of 688796 and an issue price of 26.68 yuan per share, resulting in a high price-to-earnings ratio of 519.12 times [1] - Bai'ao Saitou specializes in drug development and preclinical research, offering services such as gene editing, pharmacological efficacy evaluation, model animal sales, antibody development, and innovative drug development [1] - By the end of the trading day, Bai'ao Saitou's stock price increased by 146.6% from its issue price, with a trading volume of approximately 1.67 billion yuan and a turnover rate of 75.8% [1] Stock Performance Analysis - Excluding Bai'ao Saitou's first-day performance, the average increase for the remaining 594 stocks on the Sci-Tech board was approximately 0.01%, with an average turnover rate of 2.37% and a total trading volume of about 178.675 billion yuan [2] - In individual stock performance, Huo Lai Wo reached the daily limit, marking the highest increase, while Jia Hua Technology experienced the largest decline at 10.1% [2] - In terms of trading volume, Mo'er Thread led with a volume of 10.82 billion yuan, while Hanbang Technology had the lowest at 731.4 million yuan [2] - Mo'er Thread also had the highest turnover rate at 51.93%, while Zhongfu Shenying recorded the lowest at 0.14% [2]

Investment Rating - The investment rating for the company is positioned in the mid-to-lower range, with an AHP score of 2.38, placing it in the 38.9% percentile of the overall score [2][5]. Core Insights - The company, Baiaosaitu, is a leading preclinical CRO and biotechnology firm, focusing on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development. The gene editing technology is a significant foundation for its business, having developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [2][12]. - The company has expanded its business into innovative model animal sales, having developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice. The establishment of a production center compliant with AAALAC international standards supports large-scale breeding and supply of model animals [12][30]. - The company has established a comprehensive pharmacology and efficacy evaluation system, serving approximately 950 partners globally and completing over 6,350 drug evaluation projects. It has collaborations with 9 of the top 10 global pharmaceutical companies in the pharmacology and efficacy sector [2][18]. Summary by Sections AHP Score and Expected Allocation Ratio - The AHP score for Baiaosaitu is 2.38, indicating a mid-to-lower performance level in the AHP model [5][6]. Company Fundamentals and Highlights - Baiaosaitu has built platforms for gene editing, model animal breeding, preclinical pharmacology evaluation, and antibody drug development, evolving from a single-service biotechnology company to a leading biopharmaceutical enterprise [6][12]. - The company’s revenue composition shows that model animal sales accounted for approximately 44% of total revenue in the first half of 2025, followed by antibody development and preclinical pharmacology services [7][8]. Financial Comparison with Peers - From 2022 to the first half of 2025, Baiaosaitu's revenue was lower than that of comparable companies, with revenues of 5.34, 7.17, 9.80, and 6.21 billion yuan respectively. However, the net profit turned positive in 2024, with a net profit margin that improved over time [22][24]. - The company’s gross margin was relatively high, with figures of 73.38%, 70.59%, 77.67%, and 74.39% from 2022 to the first half of 2025, outperforming the average of comparable companies [24][25]. Fundraising Projects and Development Vision - The company plans to raise funds for projects including the construction of a drug early research service platform, antibody drug research and evaluation projects, and preclinical research projects, which are expected to enhance its core competitiveness and solidify its industry position [30][31].